Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive® 1
  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive® 2
  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive® 3
Product Description

  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated – Healive®
Launched in 2002

Hepatitis A & Hepatitis B Combined Vaccine – Bilive®
Launched in 2005

Healive® is:
Prequalified by the World Health Organization.
Provides sustained protection for over 30 years after full immunization, according to model predictions.
Has a good safety profile and can be used in people with special health conditions.
Exported to more than 30 countries and used in many national immunization programs, after two decades in the marketplace.

In 2005, SINOVAC launched a combination vaccine against hepatitis A and B based on Healive®. It provides simultaneous protection against both diseases.

Read more on http://www.sinovac.com/Vaccines/Hepatitis_A_Vaccine-en.html

Read more Show less

Sinovac Biotech Ltd.

  • CN
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Brand Name; Immune Health; Product Features
  • Supplied from
    China
More specifications Fewer specifications
Sales Markets
Show more Show less

Sinovac Biotech Ltd.

  • CN
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research
View company profile

More Products from Sinovac Biotech Ltd. (3)

  • Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

    Product Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

    Launched in 2021.

    Prequalified by the World Health Organization.

    Manufacturing process is result of technology transfer from the WHO and Netherlands-based lntravacc.

    Good safety with zero preservatives and antibiotics.

    Read more on: http://ww...
  • Influenza Vaccine (Split Virion), lnactivated – Anflu®

    Product Influenza Vaccine (Split Virion), lnactivated – Anflu®

    Influenza Vaccine (Split Virion), lnactivated – Anflu®
    Pandemic Influenza Vaccine, lnactivated, Adjuvanted – Panflu®
    H1N1 Influenza A Vaccine (Split Virion), lnactivated – Panflu.1®
    Influenza Vaccine (Split Virion), lnactivated, Quadrivalent – TetrAnflu®

    Anflu®, preservative-free ...
  • SYN023 (Zamerovimab and Mazorelvimab Injection)

    Product SYN023 (Zamerovimab and Mazorelvimab Injection)

    Zamerovimab and Mazorelvimab Injection (SYN023) is the World’s First Humanized mAb Cocktail against Rabies. It has approved in China since 2024. 

Sinovac Biotech Ltd. resources (2)

  • SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia

    News SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia

    Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.

    14 Jul 2021
  • SINOVAC Vaccines leaflets

    Brochure SINOVAC Vaccines leaflets

    Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

    SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.